<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873065</url>
  </required_header>
  <id_info>
    <org_study_id>LivzonIY-81149R-11-02</org_study_id>
    <nct_id>NCT02873065</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Livzon Pharmaceutical Group Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Livzon Pharmaceutical Group Inc.</source>
  <brief_summary>
    <textblock>
      This study compared efficacy and safety of Ilaprazole based triple regimen therapy including
      Ilaprazole 5mg, Clarithromycin 500mg and Amoxicillin Cap(Amoxicillin) 1000mg BID on the first
      line eradication treatment of H.pylori
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants are defined as persons who have endoscopically confirmed on gastric or duodenal
      ulcer(including scar stage) ,gastritis and dyspepsia confirmed to be H.pylori positive
      patients in the biopsy and UBT test. For 7 days, Participants treated as Esoprazole based
      triple regimen therapy therapy including Esoprazole 20mg，Clarithromycin 500mg and Amoxicillin
      Cap(Amoxicillin) 1000mg BID. After treatment, The healing rate was evaluated in the UBT test
      and Biopsy at 49±5days from the first day dosing
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date>June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate of Helicobacter pylori as assessed by UBT test</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of side effects of each treatment</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Helicobacter Pylori Eradication</condition>
  <arm_group>
    <arm_group_label>Ilaprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ilaprazole -based quadruple therapy for 7days：Ilaprazole -based quadruple therapy for 7days: Ilaprazole 5mg bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esoprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ilaprazole</intervention_name>
    <arm_group_label>Ilaprazole</arm_group_label>
    <other_name>Ilaprazole and amoxicillin 1000mg bid, clarithromycin 500mg bid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esoprazole</intervention_name>
    <arm_group_label>Esoprazole</arm_group_label>
    <other_name>Esoprazole and Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have endoscopically confirmed on gastric, duodenal ulcer(including scar)
             or gastritis confirmed to be H.pylori positive patients in the biopsy and UBT test.

          -  Subject who fully understands conditions of clinical trial.

          -  Subject who agrees to participate and spontaneously sign the ICF

        Exclusion Criteria:

          -  Known hypersensitivity to any component of ilaprazole, Esoprazole, Amoxicillin and
             Clarithromycin

          -  Subjects who are taking contraindicated medications for experimental and concomitant
             drug

          -  Administrated of PPI, antibiotic medication within 4 weeks prior to commencement of
             the study

          -  Pregnant and/or lactating women

          -  Reproductive aged women not using contraception

          -  Uncontrolled diabetics

          -  Uncontrolled hypertension

          -  Uncontrolled liver dysfunction

          -  Alcoholics

          -  Subjects with a history of digestive malignancy within 5 years

          -  Subjects with a history of gastrectomy or esophagectomy

          -  Subjects with hereditary diseases such as Galactose intolerance, Lapp lactose
             deficiency, glucose-galactose malabsorption

          -  Subjects participating in a clinical trial before another trial within 30 days

          -  Inconsistent judged subject by researcher
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>August 16, 2016</last_update_submitted>
  <last_update_submitted_qc>August 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

